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Abstract
Background: Uterine fibroids are the most common benign tumor in women, and surgical intervention is still the
main fibroid treatment. Patient demands have encouraged development of less-invasive methods such as
high-intensity focused ultrasound (HIFU). This study aimed to evaluate the safety and effectiveness of magnetic
resonance-guided high-intensity focused ultrasound therapy using a volumetric ablation technique in the
treatment of symptomatic uterine fibroids in China.
Methods: One hundred and seven patients were enrolled and treated with magnetic resonance-guided high-
intensity focused ultrasound in this study. Clinical efficacy was based on the proportion of patients with fibroid
shrinkage (10 % volume reduction or more compared to baseline) at 6 months post treatment as measured
with magnetic resonance imaging. The quality of life and symptom outcome was assessed using the uterine
fibroid symptom and quality of life questionnaire with symptom severity scoring. Safety was primarily assessed
by evaluating the reported adverse events.
Results: Ninety nine of the 107 treated patients had fibroid shrinkage at 6 months post treatment. Resulting in
an overall 93 % (95 % confidence interval 86–97 %) treatment success rate, p value <0.001; the symptom severity
scoring and health-related quality of life at 6 months was statistically different from the screening symptom severity
scoring at 0.05 level. Of 366 adverse events reported, there were no study procedure-related or device-related serious
adverse events were in the study.
Conclusions: This study demonstrated that the volumetric magnetic resonance-guided high-intensity focused
ultrasound device is safe and technically effective and can be utilized in clinically efficient treatments of symptomatic
uterine fibroids.
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Background
Uterine fibroids are the most common benign tumor in
pre- and peri-menopausal women. As fibroids increase in
size, they can produce pain, menorrhagia, fertility problems,
pressure, bloating, and urinary and bowel compression
symptoms [1–4].
Treatment options for symptomatic uterine fibroids
include surgery (myomectomy or hysterectomy), drug
treatment (gonadotropin-releasing hormone analogs) [5],
minimally invasive techniques such as uterine artery
embolization (UAE) [6–8], and cryotherapy [9, 10]. Even
though surgical interventions of uterine fibroids have been
the most common treatment option, it requires anesthesia,
hospital stays, and long recovery periods. It has been
estimated that 600,000 hysterectomies are performed
per year in the USA and more than half of the conducted
hysterectomies are due to fibroids [11, 12]. Recently,
patient demands have encouraged development of less-
invasive methods such as UAE, ultrasound-guided high-
intensity focused ultrasound (US-HIFU) and magnetic
resonance-guided high-intensity focused ultrasound (MR-
HIFU).
In HIFU treatment, the beam of HIFU penetrates
through soft tissue creating localized high temperatures
(55 to 70 °C) for a few seconds within the target, thus
producing irreversible cell damage and coagulative necro-
sis. Applying HIFU energy to a fibroid tissue requires treat-
ment planning, targeting of the US beam to the desired
locations and monitoring of the energy delivery. In some
applications, this can be performed using diagnostic US
imaging in combination with the HIFU. While diagnostic
US provides some anatomical details, helps with treatment
planning and targeting, and has a strength in terms of
motion, for instance, fibroid motion caused by respiration
or motion of adjacent bowel that can cause artifact in MR
imaging, it does not provide 3D planning or means of
measuring the temperature increase. MR imaging provides
a non-invasive temperature measurement, thermal dose
quantification in the target tissue, utilizing the proton-
resonance frequency (PRF) shift phenomena to monitor
the temperature [13], and continuous imaging of the fi-
broid and surrounding structures such myometrium,
bowel, and sacral nerves.
Previous studies have shown that MR-HIFU is capable
of reducing the fibroid size and fibroid-related symptoms
while maintaining an excellent safety profile [14–29]. In
these studies, ablation of fibroid volumes is either done by
the conventional approach, point-by-point technique, or
by a volumetric heating technique. The first one is per-
formed by iterative sonication of a single focal point, with
each sonication followed by a cooling period. However,
with this approach, a relatively large portion of the deliv-
ered energy is lost via diffusion of heat out of the small
targeted region, and long treatment times are required.
On the other hand, a volumetric heating technique where
the focus of the ultrasound beam is electronically steered
along a trajectory comprising of multiple outward-moving
concentric circles with an axial diameter of 4–16 mm has
been introduced [22, 30, 31].
The aim of this study was to evaluate the safety and
effectiveness of MR-HIFU therapy using a volumetric
ablation technique in the treatment of symptomatic uter-
ine fibroids in China.
Methods
This study was a multi-center, single arm, non-randomized
clinical trial to evaluate the safety and effectiveness of
volumetric MR-HIFU system in the treatment of symp-
tomatic uterine fibroid patients (sponsored by Philips,
clinicaltrials.gov identifier NCT01588899). Local ethics
committee approval was obtained from both Peking
University First Hospital and the First Affiliated Hospital,
Xi’an Jiaotong University for the protocol prior to study
initiation. Written informed consent was obtained from
each patient at the screening visit prior to the initiation of
any study-related procedures.
A total of 350 patients were screened for the trial, out
of which 107 were included. Inclusion criteria were as
follows: (1) women aged >18 years; (2) weight <140 kg;
(3) pre- or peri-menopausal; (4) MR-HIFU device acces-
sibility to treat at least 50 % of the total fibroid volume;
(5) total planned ablation volume of all fibroids should
not exceed 250 ml; (6) dominant fibroid (diameter) is
greater than or equal to 3 cm; (7) no highly perfused or
brighter than myometrium in T2-weighted MRI (a.k.a.
type 3 per Funaki classification [32]); and (8) willing and
able to attend all study visits. Exclusion criteria were as
follows: (1) other pelvic disease; (2) desire for future preg-
nancy; (3) positive pregnancy test; (4) hematocrit <25 %;
(5) surgical clips in the direct path of the HIFU beam; and
(6) MRI contrast agent contraindicated.
All therapies were conducted using a clinical MR-HIFU
system (Sonalleve V2, Philips, Best, the Netherlands) inte-
grated into a 1.5T MR scanner at Xi’an site and 3.0T MR
at Peking site (Achieva, Philips, Best, the Netherlands).
The details of the MR-HIFU system and treatment proce-
dures have been described elsewhere [16]. T2-weighted
(T2W) 3D turbo spin-echo (TSE) images were ac-
quired for screening and treatment planning. RF-spoiled
gradient-recalled EPI sequence used for real-time therm-
ometry had three coronal slices perpendicular to the beam
axis, centered at the focal-region and one sagittal slice
aligned along the beam propagation direction and two
additional slices were positioned to monitor potential
excessive near field (i.e., on the skin) and far-field
(Fig. 1a–d). Immediately after HIFU treatment and at
follow-ups, a contrast-enhanced T1-weighted (CE-T1W)
image was acquired.
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Patient immobilization time was limited to 3 h due to
the risk of deep venous thrombosis. For analgesics, all
patients received 200 mg Celebrex at Peking site and
oxycodone hydrochloride and Paracetamol (acetamino-
phen) tablets (5 mg) at Xi’an site.
Study endpoints
The primary endpoints
The primary endpoint of the study, clinical efficacy, was
based on the proportion of treated patients with fibroid
shrinkage as measured with MRI without additional
treatment (myomectormy, hysterectomy, uterine artery
embolization, or MR-HIFU) during the follow-up period
[20, 25, 26]. An image-based primary endpoint was se-
lected in order to be in line with the Chinese SFDA No-
tice 222 (2007): Notice on the issuance of the relevant
technical requirements for HIFU device.
Women were defined as having fibroid shrinkage, i.e.,
treatment success at 6 months if the total volume of
their treated fibroids plus measurement error estimate
was 90 % or less then than the baseline fibroid volume
minus measurement error estimate. Similarly, women were
considered as treatment failures (no fibroid shrinkage) if
the total volume of their treated fibroids at 6 months plus
measurement error estimate was more than 90 % of the
total baseline fibroid volume minus measurement error.
The estimation of the measurement error was based on
intra-reader variability and was calculated by the core la-
boratory responsible for image evaluation. Fibroid volume
was estimated by manual segmentation on T2W MRI at
baseline (treatment day, prior to treatment) and at 1, 3,
and 6 months post treatment. Measurements were per-
formed by an independent reader (CRO’s core lab) blinded
to the patient information. All patients who underwent
HIFU treatment were to be included in the primary effi-
cacy analysis.
In addition to the primary endpoint expressed as a bin-
ary variable, the percent reduction in fibroid volume was
also calculated using the following formula:
% Reduction ¼ Total Volume at Baseline −Total Volume at 6 months
Total Volume at Baseline
 100
The secondary endpoints
In this study, the secondary endpoints were chosen to
match endpoints commonly used internationally in the
field of fibroid follow-up.
 Evaluation of the non-perfused volume assessed by
MRI: The non-perfused volume (NPV) was estimated
using a manual contour segmentation on CE-T1W
images immediately post treatment, 1, 3, and 6 months
Fig. 1 Multiplane MR thermometric images acquired during sonication with a 12-mm treatment cell (frequency, 1.2 MHz; acoustic power, 190 W)
with visualization of the ultrasound focus in a coronal view, b sagittal view, and c coronal view from the near field and d oblique view from the
far field
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post treatment. Lesion NPV measurements were
performed by an independent reader (CRO’s core lab)
blinded to the patient information. The percentage
of the fibroid volume that was non-perfused was
calculated as follows:
NPV %ð Þ ¼ Non ‐perfused Volume
Fibroid Volume
 100
 Evaluation of The Uterine Fibroid Symptom and
Quality of Life (UFS-QoL) questionnaire with symptom
severity scoring (SSS): UFS-QoL questionnaire was
completed at screening, 1, 3, and 6 months post
treatment. The UFS-QoL has seven subscales (i.e.,
SSS, concern, activities, energy/mood, control, self-
conscious, and sexual function) and was validated
in a study comparing scores between women with
normal menstrual cycles and women with symptomatic
fibroids [3]. The SSS (questions 1 to 8) ranges from 8
to 40 (i.e., range = 32). Higher transformed SSS values
are indicative of greater symptom severity or bother
and lower scores indicate minimal symptom severity.
The HRQL has six subscales (i.e., concern, activities,
energy/mood, control, self-conscious, and sexual
function). Each subscale was created by summing
the scores of the items. Higher transformed HRQL
score is an indicative of better quality of life. The
transformed SSS score and transformed HRQL used
in this study analysis were calculated as described by
Spies et al. [3].
The safety endpoints
Adverse events (AEs) were based on patient self-report
and collected by recording the self-reported symptoms
at site visits and during telephone contacts. AEs includ-
ing serious adverse events (SAEs) were reviewed by the
sponsor and the clinical events committee (CEC). SAEs
were defined according to the Society of Interventional
Radiology guidelines [33].
Statistical analysis
The primary analysis tested the null hypothesis, which
the proportion of treated women with fibroid shrinkage
would be equal to 0.70, against the alternate hypothesis,
which the proportion with fibroid shrinkage would be
greater than 0.70. This hypothesis was evaluated using
Table 1 Patient demographics, number and type of fibroids
Variable Category Peking (N = 58) Xi’an (N = 49) Overall (N = 107)
Age (years) Mean (SD) 45.1 (4.50) 43.9 (4.50) 44.5 (4.50)
Weight (kg) Mean (SD) 62.2 (7.60) 58.5 (7.80) 60.5 (7.90)
BMI (kg/m2) Mean (SD) 24 (2.40) 22.8 (2.60) 23.5 (2.60)
Ethnicity Asian 57 (98.3 %) 49 (100 %) 106 (99.1 %)
Caucasian 1 (1.7 %) 0 (0.0 %) 1 (0.9 %)
Number of fibroids Total number 77 53 130
Mean (SD) 1.3 (0.50) 1.1 (0.30) 1.2 (0.50)
Type of fibroid Intramural 42 (54.5 %) 45 (84.9 %) 87 (66.9 %)
Submucosal 5 (6.5 %) 2 (3.8 %) 7 (5.4 %)
Subserosal 30 (39.0 %) 6 (11.3 %) 27.7 %)
Fig. 2 Flowchart of patient screening and enrollment
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data for both sites and a two-sided exact-binomial Z-test
at the 0.05 significance level. Exact Clopper-Pearson 95 %
confidence interval for the proportion of patients with
fibroid shrinkage at 6 months was calculated.
In addition, the primary analysis was repeated with fi-
broid shrinkage and was defined more conservatively,
that is the proportions of patients with ≥10, ≥20, ≥30, ≥40,
and ≥50 % reduction in fibroid volume at 6 months was
estimated, with the Exact Clopper-Pearson 95 % confi-
dence interval for the proportions calculated overall and
by site. The proportion of patients with fibroid shrinkage
1, 3, and 6 months post treatment with 95 % CI was also
calculated. Also, the percent reduction in fibroid volume
at 1, 3, and 6 months follow-up were calculated based on
fibroid volume measured using MRI. The NPV based on
MRI was summarized by site and overall.
The transformed SSS and seven UFS-QoL subscales
were summarized for baseline, 1, 3, and 6 months post
treatment. The number of observations, mean, standard
deviation, and 95 % CI for the raw values and for change
from baseline were presented by site and overall.
Statistical analyses were performed using SAS (ver. 9.3,
SAS Institute Inc., Cary, NC 27513, USA).
Results
Patient demographics
Three hundred fifty women were screened, and 107
(30.6 %) of them underwent HIFU treatment. A summary
of patient screening is shown in Fig. 2. Findings from the
MRI screening which includes presence of vertical scar
tissue, bowel interference, patients with more than five
symptomatic fibroids, fibroids that are too large (>250 cm3)
or too deep (skin to fibroid center >10 cm), highly per-
fused fibroid with excessive vascularity (Funaki type 3),
pedunculated fibroids were the most frequent reason
(i.e., 69.5 %) for a patient not to be enrolled. Also, 29.6 %
of the screened women withdrew from study prior to
enrollment. All of the 107 treated patients completed
the 1-month follow-up visit, 102 (95 %) completed the
3-month visit, and 100 (93 %) completed the 6-month
visit. A summary of patient demographics is presented
in Table 1. No MR-HIFU therapies were canceled due
to technical failures.
Primary efficacy results
Reduction in fibroid volume: patient level analysis
The overall proportion of women with treatment success
(the total fibroid volume of treated fibroids at 6 months
plus the error estimate was 90 % or less than the total fi-
broid volume of treated fibroids at baseline minus the
error estimate) was 0.93 (95 % CI 0.86–0.97). The error
estimate was based on intra-reader variability calculated
by the core laboratory responsible for the image evalu-
ation. The proportion of treatment success is significantly
higher than the null hypothesized value of 0.70 for overall
and for each site, p value <0.001. Treatment success was
reported in 52 of the 58 (90 %) patients treated at the
Peking site and 47 of the 49 (96 %) patients treated in
Xi’an Jiaotong site. Table 2 shows the number and propor-
tion of patients with fibroid shrinkage by study site and
overall.
Reduction in fibroid volume: fibroid level analysis
The proportion of patients with ≥10, ≥20, ≥30, ≥40, and
≥50 % reduction in fibroid volume 6 months post
Table 3 Proportion of patients with reduction in total fibroid
volume at 6 months
Reduction in total
fibroid volume (%)
Peking (N = 58) Xi’an (N = 49) Overall (N = 107)
≥10 0.90 (0.79, 0.96) 0.96 (0.86, 1.00) 0.93 (0.86, 0.97)
≥20 0.89 (0.77, 0.96) 0.87 (0.74, 0.95) 0.88 (0.80, 0.94)
≥30 0.76 (0.62, 0.87) 0.74 (0.59, 0.86) 0.75 (0.65, 0.83)
≥40 0.69 (0.54, 0.80) 0.52 (0.37, 0.67) 0.61 (0.51, 0.71)
≥50 0.46 (0.33, 0.60) 0.30 (0.18, 0.46) 0.39 (0.29, 0.49)
Table 4 Percent reduction in fibroid volume measured by MRI
Months post treatment
Site Parameter 1 3 6
Peking No. patients 58 54 54
Mean (SD) 20.6 (23.00) 43.3 (25.10) 51.3 (21.60)
95 % CI (14.6, 26.6) (36.4, 50.1) (45.4, 57.2)
Xi’an No. patients 49 45 46
Mean (SD) 20.1 (16.60) 39.6 (19.40) 48.8 (19.00)
95 % CI (15.3, 24.9) (33.8, 45.4) (43.2, 54.5)
Overall No. patients 107 99 100
Mean (SD) 20.4 (20.20) 41.6 (22.70) 50.2 (20.40)
95 % CI (16.5, 24.2) (37.1, 46.1) (46.1, 54.2)
Table 5 Summary non-perfused fibroid volume percent (%NPV)
based on MRI evaluation (treatment visit)
Variable Category Peking (N = 58) Xi’an (N = 49) Overall (N = 107)
%NPV No. patients 57 49 106
Mean (SD) 55.7 (21.10) 53.7 (21.30) 54.8 (21.20)
95 % CI (50.1, 61.3) (47.5, 59.8) (50.7, 58.8)
%NPV percent non-perfused volume






Proportion 95 % CI P value
Peking 58 52 0.90 (0.79, 0.96) <.001
Xi’an 49 47 0.96 (0.86, 1.00) <.001
Overall 107 99 0.93 (0.86, 0.97) <.001
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treatment with the Exact Clopper-Pearson 95 % confi-
dence interval overall and by site are presented in Table 3.
The proportion of patients with at least 40 % reduction in
total fibroid volume was 0.61 (95 % CI 0.51–0.71).
Secondary efficacy analysis
Fibroid-related endpoints
The percent reduction in fibroid volume at 1, 3, and
6 months follow-up based on fibroid volume measured
using MRI both in Peking and Xi’an sites were very con-
sistent between the two sites (20.6, 43.3, and 51.3 % for
Peking site and 20.1, 39.6, and 48.85 % for Xi’an). The
number of observations, mean, standard deviation, and
95 % CI is presented in Table 4. Overall, the mean percent
reduction in fibroid volume at 6 months was 50.2 %, with
the lower bound of the 95 % CI of 46.1. This result indi-
cates that on the average, the fibroid volume reduction for
this procedure is significantly greater than 45 %. Figure 3
shows an example of the progression of fibroid volume re-
duction after successful treatment.
Table 5 provides a summary on NPV after treatment.
The mean NPV was also very consistent between the
two sites (i.e., 55.7 % for the Peking site and 53.7 % for
the Xi’an site).
Uterine fibroid symptom quality of life (UFS-QoL)
The UFS-QoL was assessed at the screening visit and
during follow-up at 1, 3, and 6 months. The overall results
of UFS-QoL are shown in Table 6. The SSS-transformed
score for both sites combined were observed to decline
over time. The SSS-transformed score at screening was
34.4, and 24.0 at 6 months post treatment. The SSS at
6 months is statistically different from the screening SSS
at 0.05 level (non-overlapping 95 % CI). At the same time,
the HRQL-transformed score increased from 73 to 82.2.
The HRQL at 6 months is statistically different from the
screening HRQL at 0.05 level (non-overlapping 95 % CI).
Adverse events
Table 7 gives an overview of AEs. A total of 366 adverse
events were reported, out of which 10 were reported as
SAEs. No deaths were reported. A large number of SAEs
is explained by four pregnancies, each of which was re-
ported as SAE when they occurred. All pregnant patients
terminated their pregnancy voluntarily while enrolled in
the trial. Each pregnancy termination was reported as a
separate SAE as well. The remaining two SAEs were due
to occurrence of breast cancer surgery (N = 1) and fibroid-
Fig. 3 An example of the progression of fibroid volume reduction after successful treatment: a T1W CE-THRIVE immediately post treatment,
b T2W image of the fibroid at treatment day (fibroid volume 144.3 ml), and c–e T2W images at 1 month (70.3 ml, % reduction 51.32 %),
3 months (31.8 ml, % reduction 74.8 %), and 6 months (23.6 ml, % reduction 83.6 %) follow-ups
Table 6 Uterine fibroid symptom severity (UFS-QoL) overall summary
Months post treatment









Mean (SD) 34.4 (14.70) 28.1 (15.00) 27.2 (15.70) 24 (16.10)
95 % CI (31.6, 37.2) (25.2, 30.9) (24.2, 30.3) (20.8, 27.2)
HRQL transformeda
Mean (SD) 73 (18.80) 78.1 (18.00) 78.5 (19.50) 82.2 (17.30)
95 % CI (69.4, 76.6) (74.7, 81.6) (74.7, 82.4) (78.7, 85.6)
Total score
Mean (SD) 79.3 (25.10) 71.3 (24.40) 70.6 (26.10) 65.4 (24.30)
95 % CI (74.5, 84.1) (66.7, 76) (65.5, 75.7) (60.5, 70.2)
SSS symptom severity score, HRQL health-related quality of life
aTransformed scores (SSS and HRQL) can range from 0 to 100. The total score ranges from 37 to a maximum of 185
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related minimally invasive surgery (N = 1). All SAEs were
considered unrelated to study procedure and device.
Out of the non-serious AEs, 159 (43.7 %) were consid-
ered to be related or possibly related to the device. Most
patients (i.e., 77.6 %) reported at least one AE related to
the device, most commonly abdominal/pelvic pain, skin
heating/pain, leg pain, and back pain. Of 159 AEs, 153
were recorded during and immediately after HIFU treat-
ment while six of them were 1–3 days after treatment.
Discussion
In this study, the effectiveness of MR-HIFU device using
a volumetric ablation technique in the treatment of symp-
tomatic uterine fibroids was measured by assessing shrink-
age of treated fibroids, which is an objective, quantitative,
imaging-based study endpoint.
The study met its pre-defined endpoint, with 93 %
(95 % CI 86–97 %) of study patients exhibiting shrinkage
of ≥10 % fibroid volume shrinkage. In this study, the
mean fibroid volume reduction at 6 months was 50.3 %
(Table 4). As shown in Table 5, this rate of success was
achieved with a mean NPV of 54.8 %. NPV as a predictor
for fibroid shrinkage and clinical success has been estab-
lished in one of the latest studies [24]. Given the adequate
level of NPV achieved in this study, the fibroid volume is
reduced as expected. Note that NPV is expected to further
improve as the operators complete their learning curve
and gain more experience in patient selection and con-
ducting the procedure [34, 35].
Patients’ SSS of the UFS-QoL questionnaire improved
after treatment. As shown in Table 6, the mean SSS was
reduced from 34 points at baseline to 24 points at 6 months
post treatment. A reduction of 10 points or more is consid-
ered clinically significant [16]. It must be noted that, in the
present population in China, patients scored their own
symptoms considerably lower, and their personal health
better, than in predicate studies. Patients with similar
demographics in Western population typically scored a
baseline of over 60 points [24] compared to 34 points
in a Chinese population. This difference can most likely
be attributed to cultural differences in self-perception.
Evidently, a mean SSS of around 30 points was sufficient
for the patients to seek treatment for their fibroid symp-
toms in this study. However, the results of this prospective
study demonstrate that the relationship between volume
reduction and symptomatic improvement in fibroids fol-
lowing MR-HIFU treatment is not a direct correlation.
In this study, AEs reported were predominantly mild.
Ten SAEs were reported, all of which were judged to be
unrelated to the treatment procedure. Reported AEs
typically relate to heating from the ultrasound beam, and
are typically manifested inter-procedurally and resolved
Table 7 Summary of adverse events
Adverse event Peking (N = 58) Xi’an (N = 49) Overall (N = 107)
Total number of adverse events 224 142 366
Patients with at least one SAE 1 (1.7 %) 5 (10.2 %) 6 (5.6 %)
Total number of serious AEs 2 (0.9 %) 8 (5.7 %) 10 (2.7 %)
Pregnancy 1 (1.7 %) 3 (6.1 %) 4 (3.7 %)
Termination of pregnancy 1 (1.7 %) 3 (6.1 %) 4 (3.7 %)
Ductal carcinoma 0 (0.0 %) 1 (2.0 %) 1 (0.9 %)
Fibroid surgery 0 (0.0 %) 1 (2.0 %) 1 (0.9 %)
Patients with at least one AE 45 (77.6 %) 38 (77.6 %) 83 (77.6 %)
Total number of related AEs 52 (23.2 %) 107 (74.8 %) 159 (43.3 %)
Abdominal/pelvic pain 30 (51.7 %) 30 (61.2 %) 60 (56.1 %)
Skin heating/pain 25 (43.1 %) 10 (20.4 %) 35 (32.7 %)
Leg pain 15 (25.9 %) 5 (10.2 %) 20 (18.7 %)
Back pain 11 (19.0 %) 2 (4.1 %) 13 (12.1 %)
Abdominal distension 3 (5.2 %) 1 (2.0 %) 4 (3.7 %)
Buttock pain 4 (6.9 %) 0 (0.0 %) 4 (3.7 %)
Leg numbness 3 (5.2 %) 0 (0.0 %) 3 (2.8 %)
Skin redness 1 (1.7 %) 2 (4.1 %) 3 (2.8 %)
1st degree skin burn 1 (1.7 %) 0 (0.0 %) 1 (0.9 %)
Leg edema/pain 1 (1.7 %) 0 (0.0 %) 1 (0.9 %)
Pubic bone pain 0 (0.0 %) 1 (2.0 %) 1 (0.9 %)
Skin edema 1 (1.7 %) 0 (0.0 %) 1 (0.9 %)
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shortly thereafter. This is in line with previous clinical
studies on MR-HIFU treatments of uterine fibroids
[18, 23]. In one patient, buttock/leg/foot pain persisted
for 44 days following the HIFU treatment; isolated similar
events have been observed previously in studies using
other MR-HIFU devices [16, 36]. An independent CEC
evaluated the reported adverse events for determination of
seriousness and causal relationship with the treatment.
The CEC concluded that most of the AEs were minor, and
the safety profile of the MR-HIFU system was acceptable.
A limitation of the study was the single-arm design.
MR-HIFU treatment was not directly compared to other
options for uterine fibroid therapy. Prior experience shows
however that randomization can be prohibitive for enroll-
ment when one arm is invasive and the other non-invasive.
To limit possible bias, an objective measurement was
chosen as primary endpoint for the study, and assessed by
an independent CRO core laboratory. The choice of an ob-
jective, a quantitative endpoint which can be independently
measured, adds strength to the study. It should be noted
however that the secondary endpoints provide symptom-
atic follow-up and present as important a result as the pri-
mary image-based endpoint.
Conclusions
This study demonstrated that MR-HIFU device using a
volumetric ablation technique is safe and technically ef-
fective and can be utilized in clinically efficient treatments
of symptomatic uterine fibroids.
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